Objective-The endothelium has a crucial role in wound healing, acting as a barrier to control transit of leukocytes. Endothelial barrier function is impaired in atherosclerosis preceding myocardial infarction (MI). Besides lowering lipids, statins modulate endothelial function. Here, we noninvasively tested whether statins affect permeability at the inflammatory (day 3) and the reparative (day 7) phase of infarct healing post-MI using contrast-enhanced cardiac magnetic resonance imaging (MRI). Approach and Results-Noninvasive permeability mapping by MRI after MI in C57BL/6, atherosclerotic ApoE −/− , and statintreated ApoE −/− mice was correlated to subsequent left ventricular outcome by structural and functional cardiac MRI. Ex vivo histology, flow cytometry, and quantitative polymerase chain reaction were performed on infarct regions. Increased vascular permeability at ApoE −/− infarcts was observed compared with C57BL/6 infarcts, predicting enhanced left ventricular dilation at day 21 post-MI by MRI volumetry. Statin treatment improved vascular barrier function at ApoE −/− infarcts, indicated by reduced permeability. The infarcted tissue of ApoE −/− mice 3 days post-MI displayed an unbalanced Vegfa (vascular endothelial growth factor A)/Angpt1 (angiopoetin-1) expression ratio (explaining leakage-prone vessels), associated with higher amounts of CD45 + leukocytes and inflammatory LY6C hi monocytes. Statins reversed the unbalanced Vegfa/Angpt1 expression, normalizing endothelial barrier function at the infarct and blocking the augmented recruitment of inflammatory leukocytes in statin-treated ApoE −/− mice. hi monocytosis disrupting resolution of inflammation at the infarct resulting in poor outcome.
I schemic heart disease is one of the leading causes of morbidity and mortality worldwide. 1 The first inflammatory phase (3-72 hours) after an obstruction of a coronary artery results in the recruitment of leukocytes by cytokines into the infarcted area to clear dead cells and matrix debris. Consequently, inflammation slowly resolves, extracellular matrix proteins are generated, and an extensive microvascular network is created during the next proliferative phase (72 hours to 7 days). 2 This process, called infarct healing, determines the functional outcome of the injured tissue. Poor infarct healing generates left ventricular (LV) dilation because of infarct expansion. 3 In most patients, myocardial infarction (MI) is a consequence of rupture or tear of an atherosclerotic plaque. Atherosclerosis results from chronic hypercholesterolemic disease of blood vessels with endothelial dysfunction. 4 The altered endothelial function in atherosclerosis disrupts tight junctions between endothelial cells, triggering leukocyte and monocyte transmigration, platelet activation, and smooth muscle cell proliferation. 4 Endothelial barrier function is necessary for regulating vascular homeostasis and permitting vascular tone, macromolecular transport, immune surveillance, and deposition of a fibrin barrier to regulate wound healing. 5, 6 VEGF (vascular endothelial growth factor) is a key cytokine for endothelial permeability that is upregulated post-MI 7 . Hypercholesterolemia elevates endothelial permeability, 8 raises plasma VEGF levels in patients, 9 and alters endothelial cell morphology. 10 Atherosclerotic apolipoprotein E-deficient (ApoE −/− ) mice exhibit endothelial dysfunction with altered permeability in large vessels associated with hypercholesterolemia and atherosclerotic lesions. 11 The amount of circulating monocytes is increased in patients with atherosclerosis 12 and in atherosclerotic ApoE −/− mice. 13 After MI, infarct healing in ApoE −/− mice is severely hampered with Ly6C hi monocytosis disrupting resolution of inflammation at the infarct resulting in poor outcome.
14 Because endothelial cells constitute the majority of noncardiomyocytes in the heart, 15 endothelial dysfunction at the infarcted myocardium in atherosclerotic ApoE −/− mice could have a major effect on infarct healing.
Statins are lipid-lowering drugs approved in patients with elevated serum cholesterol levels and significantly decrease cardiovascular morbidity and mortality even in patients with low cholesterol levels. 16 Hence it has been shown that statins exert lipid-independent effects on multiple targets beyond their impact on serum cholesterol levels, including improvement of endothelial function and antithrombotic, anti-inflammatory, and antiangiogenic effects. 17 The use of statins in wild-type animals has been shown to attenuate LV remodeling. 18 Also, the early use of statins in patients after an acute MI has shown a more favorable outcome. 19 Compared with wildtype mice, atherosclerotic mice exhibit reduced infarct healing and mimic more accurately the clinical context of infarct patients with atherosclerosis preceding an MI 14 . The multifaceted process of infarct healing and adverse remodeling in atherosclerotic hearts post-MI with respect to statin treatment remains unclear because early biomarkers for the prediction and prevention of heart failure are limited.
Noninvasive magnetic resonance imaging (MRI) provides a powerful tool to serially probe dynamic biological processes of infarct healing in individuals over time and to correlate the early biological processes with outcome. We recently developed an MR tool to assess in vivo myocardial endothelial function. 20 Myocardial albumin-based imaging has previously been applied in the postinfarcted heart. 21 This was, however, not 3-dimensional and not based on myocardial T 1 mapping using retrospective gating 22 enabling the precise analysis of the dynamics of the contrast agent in the entire mouse heart. 20 The albumin-based MRI technique allowed to measure cellular processes of infarct healing correlated with structural and functional cardiac outcome, otherwise difficult to measure longitudinally. Early after MI, VEGF-mediated vascular permeability at the infarct by hypoxic conditions contributes to damaging edema formation. 7, 23 It remains unclear how VEGFmediated leakage modulates infarct healing post-MI. In this study, we explored cardiac endothelial barrier function after MI as a potential prognostic biomarker for adverse LV remodeling in ApoE −/− mice by albumin-based dynamic contrastenhanced (DCE) MRI. Furthermore, we tested how statin treatment affects endothelial barrier function at the infarct and thereby alters inflammatory recruitment into the infarct and infarct expansion with subsequent cardiac outcome in ApoE −/− mice. In vivo and ex vivo studies are illustrated in Figure 1 .
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Noninvasive MRI of Cardiac Function and Myocardial Permeability
First, in vivo cardiac measurements were performed in healthy wild-type C57BL/6, ApoE −/− , and statin-treated ApoE −/− mice to characterize endothelial barrier function at baseline. Albumin-based DCE-MRI revealed myocardial permeability surface area product close to zero, which seemed similar among wild-type C57BL/6, ApoE −/− , and statin-treated ApoE −/− mice ( Figure 2A and 2C). To test whether comparable initial myocardial function and infarct size post-MI were present at day 1 after MI, functional cardiac MRI and LGE MRI were performed. Similar initial ejection fraction (EF) and infarct size were measured among the 3 groups at day 1 post-MI ( Figure 2B , 2D, and 2E).
To assess endothelial barrier function during the inflammatory (day 3 post-MI) and proliferative phase (day 7 post-MI) of infarct healing, permeability was in vivo assessed at the infarct. At day 3 post-infarct, a significant increase in infarct permeability was observed in ApoE −/− mice compared with C57BL/6 mice. Statin treatment in ApoE −/− mice inhibited infarct permeability at day 3, displaying permeability values similar to C57BL/6 mice ( Figure 3A and 3C) . At day 7 post-infarct, an even larger increase in infarct permeability was observed in ApoE −/− mice compared with C57BL/6 mice. At day 7 post-MI, statin treatment continued to significantly reduce infarct permeability in 
Functional Cardiac MRI Follow-Up After MI
To assess the prognostic value of the noninvasive MR permeability findings after MI, we evaluated in parallel functional cardiac changes in the same cohorts of mice ( Figure 
Ex Vivo Histological Validation of In Vivo Infarct Permeability Measurements at Days 3 and 7 Post-MI
Infarct permeability was investigated using ex vivo histology. Coinjection of Evans Blue-a standard method to assess vascular leak-and albumin revealed visual colocalization at the infarct 3 days post-MI ( Figure 5A ). An excellent correlation of percent fluorescent area of Evans Blue and fluorescein isothiocyanate albumin in infarcted hearts was registered ( Figure 5B ). Infarcted hearts of separate cohorts of mice were collected on days 3 and 7 post-MI after injection of fluorescently labeled MR contrast agent to validate the in vivo MR permeability data. Representative images showed an enhanced amount of rhodamine-labeled albumin in ApoE −/− infarcts compared with C57BL/6 mice at both days post-MI. Statin treatment in ApoE −/− mice completely inhibited the increased permeability post-MI ( Figure 5C through 5G) . Quantification of the percent area rhodamine-labeled albumin confirmed the increased leakiness in ApoE −/− infarcts, versus leakiness in C57BL/6 infarcts . A and C, Baseline permeability surface area product (PS) by dynamic contrast-enhanced magnetic resonance imaging (MRI) appeared similar among all groups. B and D, Late gadolinium-enhanced (LGE) MRI (arrows) after gadolinium administration showed similar infarct size at day 1 after myocardial infarction (MI). E, Ejection fraction (EF) was similar among all groups at day 1 post-MI.
and statin-treated ApoE −/− infarcts ( Figure 5D and 5E). The amount of rhodamine-labeled albumin in infarcts correlated with in vivo MR permeability values ( Figure 5F and 5G).
In addition, immunohistochemistry revealed more red Mac-3 staining in ApoE −/− infarcts than in C57BL/6 and statintreated ApoE 
Quantification of Inflammatory Cells and Gene Expression in Infarcts at Day 3 After MI
The inflammatory reaction of infarct tissue was investigated further and quantified at day 3 post-MI because changes in permeability occurred from this time point onward in infarct healing. In an attempt to explain the increased permeability in ApoE −/− mice, the expression levels of key genes regulating endothelial function were studied at baseline and after MI (Figure 6 ). At baseline, no differences in cardiac Vegfa expression were found among the 3 groups. A higher baseline cardiac Angpt1 (angiopoetin-1) expression was observed in ApoE −/− and statin-treated ApoE −/− mice compared with wildtype C57BL/6 mice. Yet the Vegfa/Angpt1 ratio appeared not to be different among the groups at baseline (Figure 6A through 6C). Three days after MI, ApoE −/− mice showed higher Vegfa and reduced Angpt1 expression compared with C57BL/6 and statin-treated ApoE −/− mice ( Figure 6D and 6E). These alterations in Vegfa and Angpt1 expressions resulted in significantly increased Vegfa/Angpt1 ratios in ApoE −/− mice. Statin-treated ApoE −/− mice had similar Vegfa/Angpt1 ratio as C57BL/6 controls ( Figure 6F ). The unbalanced Vegfa/Angpt1 expression is linked to the presence of immature leaky vessels. 24, 25 The enhanced MRI-derived infarct permeability on day 3 post-MI positively correlated with Vegfa/Angpt1 ratio ( Figure 6G ). These findings directly associated enhanced vascular permeability with unbalanced Vegfa/Angpt1 displayed in ApoE −/− mice compared with C57BL/6 animals after infarction.
As inflammatory cells recruited to the infarct, in particular monocytes and macrophages, are a major source of VEGFA production, 26 we further investigated the number of these cells in infarct tissue of the different groups. A higher number of CD45 + leukocytes, monocytes, and inflammatory Ly6C hi monocytes in ApoE −/− infarcts was observed compared with C57BL/6 and statin-treated ApoE −/− infarcts ( Figure 6H through 6J) 
Discussion
Endothelial barrier function contributes to wound healing through basement membrane degradation and widening of gap junctions between endothelial cells allowing proteins and cells to penetrate to the injured area. 6, 27 Endothelial dysfunction is fundamental in atherosclerosis-the disease initiating an MI in most patients. Although statins have been shown to improve endothelial function 17 and ameliorate infarct healing in wild-type hearts, 18 statin treatment has not yet been explored post-MI in the ApoE −/− mouse model with poor infarct healing. In this study, the effect of statins on endothelial barrier function was noninvasively assessed in atherosclerotic ApoE −/− mice during infarct healing post-MI. Here, we showed noninvasively that vascular permeability in ApoE −/− infarcts was higher than in C57BL/6 infarcts at days 3 and 7 post-MI measured by albumin-based DCE-MRI, correlating with adverse remodeling of the LV at day 21 post-MI. Statins could reduce permeability of ApoE −/− infarcts, resulting in an improved function of statintreated ApoE −/− hearts at day 21 after MI. Ex vivo readouts displayed unbalanced Vegfa/Angpt1 expression (explaining the enhanced leakage 24, 25 ) at ApoE −/− infarcts with enhanced recruitment of CD45 + leukocytes and inflammatory Ly6C hi monocytes to the ApoE −/− infarct. Statins inverted the unbalanced Vegfa/ Angpt1 expression, normalizing endothelial barrier function during infarct healing, while hindering the increased recruitment of inflammatory leukocytes into statin-treated ApoE −/− infarcts. Acutely (within 6 hours after MI) VEGF-mediated permeability can exacerbate edema and tissue injury increasing infarct size. 6, 23 In our infarct study, we visualized similar infarct sizes at day 1 post-MI among the 3 groups by LGE MRI. However, little is known about the subacute phase of infarct healing. Here, we postulated that during the inflammatory and proliferative phase after MI, endothelial barrier function directs crucial processes of infarct healing allowing movement of fluids and molecules and transmigration of leukocytes between vascular and extravascular compartments. We, therefore, aimed to assess subacute effects (days 3 and 7 post-MI) of endothelial barrier function on infarct healing. We noninvasively revealed impaired endothelial function in atherosclerotic ApoE −/− hearts at days 3 and 7 after MI compared with wild-type C57BL/6 infarcts using MRI-based permeability mapping. When treated with statins, ApoE −/− mice displayed improved endothelial barrier function.
The use of serial noninvasive imaging allowed direct correlation between infarct endothelial barrier function by MR permeability 20 with end-diastolic volume 3 weeks after MI. Specifically, early permeability mapping during the inflammatory (day 3) and proliferative phase (day 7) predicted adverse ventricular remodeling in atherosclerotic ApoE −/− hearts after MI. Previously, invasive detection of enhanced cardiac permeability by albumin-based Evans blue assay has been shown to indirectly correlate with reduced cardiac outcome. 24, 28 Noninvasive albumin-based DCE-MRI has been shown to be effective to measure permeability in several preclinical models. 29 Only recently, correction for respiratory and cardiac motion has been overcome for implementing this noninvasive technique to the heart. 20 Regional LGE MRI uses gadolinium that extravasates fast from the vasculature into the extracellular space to delineate infarct size impossible to track subtle changes in endothelial barrier function. The limits of regional LGE have also been illustrated by T2 MRI visualizing edema exceeding the area of LGE. 30 Cardiac imaging techniques, such as first-pass perfusion 31 and arterial spin labeling, 32 report on perfusion deficits in the ischemic area but do not measure the gatekeeper function of endothelial cells. Labeled albumin, however, is a preclinical blood pool agent at the size of blood plasma proteins usually not extravasating from the microvasculature and has been shown to be sensitive to detect delicate changes in cardiac endothelial barrier function. 20 The extravasation of albumin-binding gadofosveset in experimental 
ApoE
−/−11 and human atherosclerotic sites 33 occurring through leaky microvessels of large vessel walls has been visualized. Further, positron emission tomographic imaging of albumin has been developed to visualize vascular leakage. 34 The translation of early diagnostic MR permeability imaging tool by albumin-binding gadofosveset should be further explored in the heart; cardiac MR permeability mapping might identify early infarct patients with high risk for developing heart failure.
Enhanced infarct leakiness in ApoE −/− infarcts correlated with Vegfa/Angpt1 expression. An imbalance between enhanced vascular permeability by VEGFA production and reduced vascular maturation by Angpt1 production could result in leakage-prone vessel formation. 24, 25 Although detrimental effects of VEGF-mediated permeability with damaging edema after MI have been described, 23 beneficial outcomes by increased Vegf expression post-MI have also been shown, promoting revascularization at the damaged heart. 23 Yet several double-blind, randomized clinical trials of Vegf gene therapy in patients with coronary artery disease have proven a less-successful outcome. 35 Blocking phosphoinositide 3-kinase-Akt signaling pathway downstream of VEGFA has ameliorated infarct healing, 36 suggesting that this downstream pathway of VEGF indeed is involved. Together with our findings, this suggests a delicate optimal VEGF expression in the heart post-MI for enabling sufficient infarct healing. These results additionally imply that therapeutic VEGF induction without induced Angpt1 may result in adverse cardiac effects. The endothelium at the inflamed infarct may establish a barrier to prevent invading inflammatory leukocytes to enter the infarct and further damage cardiac function. We observed an increased amount of CD45 + leukocytes, monocytes, and inflammatory Ly6C hi monocytes in ApoE −/− infarcts, as shown previously.
14 The impaired endothelial barrier function of ApoE −/− infarcts during the inflammatory and proliferative phase after MI may permit inflammatory cells to enter the infarcted area en masse. The systemic oversupply of these Ly6C hi monocytes may in addition contribute to the increased amount of inflammatory cells in the infarct. 13 The increase in infarct permeability of ApoE −/− mice was larger at day 7 than at day 3 post-MI compared with C57BL/6 mice and statintreated ApoE −/− mice. These findings are supported by other studies that showed hampered resolution of inflammation in ApoE −/− mice with 3-fold higher myeloperoxidase activity compared with C57BL/6 infarcts on day 5 post-MI.
14,37 Augmented VEGF-induced vascular leakiness at the ApoE −/− infarcts resulted in progressive scar formation with adverse remodeling and increased volume fraction of collagen at the scar 3 weeks after MI (Graphic Abstract in the online-only Data Supplement). Notably, sustained VEGFinduced vascular leakage has been shown to promote extravasation of proteins, such as fibrinogen, which polymerizes to form fibrin in the extracellular space with enhanced infarct expansion. 6 Enhanced VEGFA expression in ApoE −/− mice has been demonstrated during plaque progression expanding atherosclerotic lesions. 38 This study similarly showed an increased amount of leukocytes and more specifically inflammatory Ly6C hi monocytes at the ApoE −/− infarcts indicating augmented inflammation with enhanced extravasation of leukocytes. VEGF stimulates endothelial cells to generate MCP (monocyte chemoattractant protein)-1, hence attracting monocytes and macrophages, boosting cell migration by increasing the permeability of the endothelial layer. 39 We further demonstrated that statin treatment improved endothelial barrier function during subacute infarct healing concomitant with a better functional outcome and reduced LV dilation in ApoE −/− mice on day 21 after MI; MR-derived permeability of the statin-treated ApoE −/− infarct seemed reduced compared with untreated ApoE −/− mice but similar to C57BL/6 mice at days 3 and 7 post-MI. Statins have previously shown to inhibit endothelial exocytosis. 40 Also, contrast uptake in the vessel wall of statin-treated ApoE −/− mice has revealed less endothelial damage and plaque development, 11 underlining the endothelial cell changes by statins. Our results show that the Vegfa/Angpt1 imbalance was restored by statin treatment in ApoE −/− mice. Statins, known to reduce cholesterol biosynthesis, have been reported to reduce VEGF-induced hyperpermeability most likely through inhibition of VEGF-mediated endothelial cell signaling by mevalonate. 41 Moreover, in hyperlipidemic patients with and without atherosclerosis, statins have proven to decrease elevated levels of VEGF. 9 Here, we additionally showed that statin treatment not only reduced the level of Vegfa but lowered the amount of leukocytes in ApoE −/− infarcts at the same time. Because statins have anti-inflammatory and antioxidant effects, 17,42 they might interrupt the vicious circle of oxidative stress and inflammation-mediated hyperpermeability in different ways. These mechanisms should be further investigated.
This study had a few limitations. Firstly, this study does not address whether statin treatment initiated after MI would improve endothelial permeability. Secondly, standard LGE MRI using low-molecular gadolinium and DCE-MRI using high-molecular gadolinium-labeled albumin cannot be performed together because both techniques use gadolinium for T1 contrast. Further, systemic levels of VEGF and inflammatory cytokines have not been explored in this study. This would be interesting because elevated serum VEGF levels post-MI have been shown to correlate with serum inflammatory markers. 43 Finally, a higher animal number could clarify whether there were differences in permeability at the remote area of the infarcted hearts among the 3 groups.
Thus, noninvasive MR permeability mapping revealed higher leakiness in ApoE −/− infarcts with an unbalanced Vegfa/ Angpt1 expression and an enhanced influx of inflammatory leukocytes, predicting reduced outcome in atherosclerotic ApoE −/− post-MI. Statins lowered permeability and reduced the transit of unfavorable inflammatory leukocytes into the infarcted tissue, consequently improving LV outcome. This indicates the importance of statin treatment for adequate infarct healing post-MI in patients. Translation of cardiac MR permeability mapping could provide early prediction for highrisk infarct patients developing heart failure.
